Heritability, platelet function, and aspirin: A link established but cause unknown

Circulation

Volumn 115, Issue 19, 2007, Pages 2468-2470

  Freedman, Jane E ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aspirin; Editorials; Platelets; Thrombosis; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID;

CARDIOVASCULAR RISK; COVARIANCE; EDITORIAL; GENETIC VARIABILITY; HERITABILITY; HUMAN; IMMUNOREACTIVITY; ISCHEMIC HEART DISEASE; PHENOTYPE; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

AFRICAN AMERICANS; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 1; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MEMBRANE PROTEINS; PHENOTYPE; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SEX CHARACTERISTICS; THROMBOPHILIA; THROMBOSIS; THROMBOXANES; VARIATION (GENETICS);

EID: 34248596348     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.699165     Document Type: Editorial

References (15)

1. Michelson AD, Frelinger AL 3rd, Furman MI. Current options in platelet function testing. Am J Cardiol. 2006;98:4N-10N.
2. Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood. 2005;106:2723-2729.
3. Burgess-Wilson ME, Cockbill SR, Johnston GI, Heptinstall S. Platelet aggregation in whole blood from patients with Glanzmann's thrombasthenia. Blood. 1987;69:38-42.
4. Frelinger AL 3rd, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2- independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006;113:2888-2896.
5. Freedman JE. The aspirin resistance controversy: clinical entity or platelet heterogeneity? Circulation. 2006;113:2865-2867.
6. Cooke GE, Liu-Stratton Y, Ferketich AK, Moeschberger ML, Frid DJ, Magorien RD, Bray PF, Binkley PF, Goldschmidt-Clermont PJ. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol. 2006;47:541-546.
7. O'Donnell CJ, Larson MG, Feng D, Sutherland PA, Lindpaintner K, Myers RH, D'Agostino RA, Levy D, Tofler GH. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation. 2001;103:3051-3056.
8. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol. 2005;46:986-993.
9. Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, Fallin MD, Wilson AF, Bray PF, Becker LC, Becker DM. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation. 2007;115:2490-2496.
10. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005;46:1705-1709.
11. Mason PJ, Chakrabarti S, Albers AA, Rex S, Vitseva O, Varghese S, Freedman JE. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol. 2005;96:1365-1369.
12. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
13. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N. Sex differences in platelet reactivity and response to low-dose aspirin therapy. Jama. 2006;295:1420-1427.
14. Bray PF, Howard TD, Vittinghoff E, Sane DC, Herrington DM. Effect of genetic variations in platelet glycoproteins Ibalpha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. Blood. 2007;109:1862-1869.
15. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103:201-206.